Benitec Biopharma Limited (NASDAQ:BNTC) Corporate Logo

Benitec Biopharma Limited – American Depositary SH (NASDAQ:BNTC) reported a decrease of 1.64% in shares shorted. FINRA published shares shorted of BNTC’s total 12,000 shares. The down change of 1.64% from 12,200 shares was reported. With Average volume 5,900, BNTC’s former position will take 2 days to recover. Benitec Biopharma Limited – American Depositary SH’s shares shorted float is 0.2%.

BNTC reached $1.45 during the last trading session after $0.03 change.Currently Benitec Biopharma Limited is downtrending after 38.55% change in last January 13, 2018. BNTC has 1,502 shares volume. BNTC underperformed the S&P 500 by 38.55%.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia and the United States.The company has $20.23 million market cap. The firm provides BB-301, a single administration ddRNAi gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi therapies for the treatment of human hepatitis B.Last it reported negative earnings. It also offers BB-401 and BB-501 for the treatment of oncology.

Another two news for Benitec Biopharma Limited (NASDAQ:BNTC) were recently released by: on December 21, 2018 with title “Benitec Provides Update on BB-401 Cancer Treatment Program – PRNewswire”. The other‘s article was titled “Benitec Biopharma provides update on OPMD orphan disease program – PR Newswire” and released on November 27, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *